Malignant tumor of the breast
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Pathological examination confirms HER2 positive: IHC result 3+ or 2+/ISH+; 2.Surgical resection or coarse needle aspiration is intended to obtain fresh tumor tissue; 3.Aged 18 to 75; 4.ECOG(Eastern Cooperative Oncology Group):0~3; 5.Voluntarily participate in this clinical trial, understand and abide by the research procedures and have signed the informed consent form; 6.There are no relative or absolute contraindications for surgery;
Exclusion criteria
Exclusion criteria: 1.Received neoadjuvant therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) before the operation; 2.Preoperative assessment or intraoperative exploration reveals that insufficient tumor tissue cannot be obtained (including inability to resect, etc.); 3.Women planning to become pregnant or women who are breastfeeding; 4.Having participated in clinical trials of other anti-tumor drugs or having received chemotherapy/targeted drug therapy within four weeks prior to signing the informed consent form; 5.The sample quality does not meet the standards for tumor organoid modeling; 6.The modeling of tumor organoids failed; 7.Immune deficiency or severe bone marrow suppression; 8.The patient already has serious liver and kidney diseases, cardiovascular diseases, blood disorders, etc; 9.Illegal use of drugs or chronic alcohol abuse or a total daily alcohol intake of more than 50 g/d; 10.Lack of autonomy, inability to walk, or inability to participate in the 6-month follow-up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SRPK1 expression level;mRNA expression level;Protein expression level; | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology